Brigham Buhler Returns to JRE With the Latest on Peptide Access
If you have been following the peptide space at all over the past two years, you know Brigham Buhler. The founder of Ways2Well has become something like the unofficial spokesman for peptide access in America, and his third appearance on Joe Rogan's podcast lands at a moment when the regulatory picture is shifting fast.
This March 2026 episode picks up where Buhler's previous JRE conversations left off. But a lot has changed. The FDA's crackdown on compounding pharmacies reached a peak in late 2025, and the fallout is still playing out. Buhler walks through what actually happened, who got shut down, and what that means for patients who were relying on compounded peptides for everything from injury recovery to metabolic health.
The Current State of Peptide Access
The big question on everyone's mind: what can you actually get right now? Buhler breaks this down in practical terms. Some peptides that were widely available through compounding pharmacies a year ago are harder to source now. Others have come back through different channels. The regulatory environment is not static, and Buhler does a good job explaining why the situation keeps changing.
One of the more interesting points he makes is about the difference between what the FDA says publicly and what is actually happening on the ground. There is a gap between official policy and enforcement reality. Some compounding pharmacies are operating in gray areas. Others have found compliant pathways that let them continue serving patients. The details matter here, and Buhler gets specific.
Why the FDA Went After Compounders
Buhler's take on the FDA's motivations is worth hearing even if you do not agree with all of it. He argues that Big Pharma pressure played a major role, particularly as GLP-1 drugs became a multi-billion dollar market. When compounding pharmacies started offering semaglutide and tirzepatide at a fraction of the brand-name price, the pharmaceutical industry had a financial incentive to push regulators toward stricter enforcement.
That is not a conspiracy theory. It is basic economics. Buhler points to specific lobbying efforts and FDA communications that support this timeline. Joe pushes back in a few places, which makes the conversation better. You get to hear the argument tested, more than presented.
BPC-157, TB-500, and What's Still on the Table
For people specifically interested in peptides like BPC-157 and TB-500 for injury recovery and gut health, Buhler gives an updated picture. These peptides have been in a strange regulatory limbo. They are not approved drugs. They are not exactly banned. The FDA has sent warning letters to some sellers while leaving others alone.
Buhler explains the current sourcing space without sugarcoating it. Quality control is a real concern when the supply chain gets pushed underground or overseas. He talks about what to look for in a provider, red flags that should make you walk away, and how the testing and verification process works for reputable compounders.
What You Can and Cannot Get in Early 2026
Buhler gets specific about the sourcing reality as of March 2026, and this is the most practically useful part of the episode. BPC-157 is available through some compounding pharmacies in certain states, but availability is patchy. Some pharmacies stopped carrying it after FDA warning letters. Others found compliant pathways and continued. TB-500 is in a similar gray zone. Growth hormone secretagogues like CJC-1295 and Ipamorelin are available through some telehealth platforms and compounding pharmacies, though the number of providers has shrunk compared to 2023.
Compounded semaglutide and tirzepatide are the most contested category. The FDA's position is that compounding pharmacies should not produce these while brand-name versions are available. Shortage designations have come and gone, creating windows of availability that close and reopen unpredictably. Buhler advises patients to work with established compounding pharmacies that have legal counsel, not fly-by-night operations.
For people sourcing from overseas or from research chemical companies, Buhler is blunt: the risks are real. Without third-party testing, you have no way to verify purity, potency, or sterility. He has seen lab results on overseas products that showed bacterial contamination, wrong concentrations, and in some cases completely different compounds than what was on the label.
Quality Control Red Flags to Watch For
Buhler lists specific warning signs that should make you walk away from a peptide provider. Any company that sells injectable peptides without requiring a prescription is operating outside the law and probably cutting corners elsewhere too. Products shipped without cold packing when the peptide requires refrigeration are likely degraded. Vials without lot numbers or expiration dates are a sign of poor manufacturing controls.
He also talks about the certificate of analysis (COA). A legitimate COA comes from an independent, accredited lab, not the manufacturer testing its own product. It should show purity above 98%, confirm the peptide identity, and test for endotoxins and heavy metals. If a seller cannot produce a third-party COA, assume the product is not trustworthy.
The Bigger Picture on Health Freedom
The conversation goes broader than just peptides. Buhler and Rogan talk about the tension between consumer access and regulatory control in health care more generally. This is the philosophical backbone of the episode. Should adults be able to make informed decisions about compounds that have research backing but lack full FDA approval? Where is the line between protection and paternalism?
These are not easy questions, and the episode does not pretend they are. But Buhler makes a persuasive case that the current system often fails the people it claims to protect. When patients who benefited from compounded peptides suddenly cannot access them, the human cost is real.
A Provider Vetting Checklist Based on What Buhler Describes
Buhler gives scattered advice throughout this episode about how to identify trustworthy peptide providers. Here it is organized into a single checklist you can use before working with any compounding pharmacy or telehealth platform.
The pharmacy should require a valid prescription from a licensed physician. No exceptions. If they sell injectable peptides without a prescription, walk away. The pharmacy should be accredited by PCAB (Pharmacy Compounding Accreditation Board) or meet equivalent state standards. Ask for a certificate of analysis (COA) from an independent, third-party lab, not the pharmacy's own internal testing. The COA should confirm purity above 98%, peptide identity, endotoxin levels, and heavy metal testing. Products should ship with appropriate cold packing if the peptide requires refrigeration. Vials should have lot numbers and expiration dates. The pharmacy should be willing to answer your questions about their sourcing and testing procedures. If they are evasive or dismissive, that is a red flag.
For telehealth platforms that connect you with prescribers and pharmacies, verify that the prescribing physician is licensed in your state and has training or experience in peptide therapy. Ask whether the physician reviews bloodwork before prescribing and requires follow-up labs during treatment. A telehealth platform that writes prescriptions based on a questionnaire alone, with no lab work and no physician interaction, is cutting corners you do not want cut when it comes to injectable medications.
Comparing the Three Buhler Episodes: Which One to Watch
This is Buhler's third appearance on JRE, and each episode serves a different purpose. If you are new to the peptide conversation, start with JRE 2079 (the first Buhler episode, covered on FormBlends). It gives you the foundations: what peptides are, how compounding pharmacies work, and the backstory on FDA restrictions. The tone is more explanatory and less political.
If you want to understand the political dynamics and the potential for regulatory change, JRE 2376 (the second episode) covers the RFK Jr. involvement, the FDA reconsideration process, and the market implications of expanded access. It is the most political of the three.
This episode, JRE 2469, is the most practical. It focuses on what is actually available right now, how to source safely, and specific quality control guidance. If you are someone who wants to use peptides and needs to know how to navigate the current market, this is the one that matters most.
Watching all three in order gives you the full picture. But if time is limited, prioritize based on what you need. Background and education: start with episode one. Policy and advocacy: episode two. Practical, current guidance: this one.
The Overseas Sourcing Problem in Detail
Buhler spends more time on overseas peptide sourcing in this episode than in his previous appearances, and for good reason. As domestic compounding access has tightened, more people have turned to international suppliers, research chemical companies, and gray-market sellers. Buhler has seen the lab results on these products, and his warnings are based on actual testing data, not speculation.
He describes seeing products from overseas suppliers that contained bacterial endotoxins above safe levels for injection. Some products had peptide concentrations 30-40% lower than what was listed on the label, meaning patients were getting a fraction of the intended dose. In the worst cases, products contained entirely different compounds than what was advertised. One batch he tested was labeled as BPC-157 but contained no detectable BPC-157 at all.
The financial math makes the temptation obvious. Domestic compounded BPC-157 from a reputable pharmacy might cost $150-300 for a treatment course. The same labeled product from an overseas seller might cost $30-50. But if the overseas product is contaminated, under-dosed, or fake, you are not saving money. You are paying for something that either does nothing or actively harms you. Buhler's position is clear: if you cannot source from a domestic compounding pharmacy with proper testing, it is better to wait than to gamble with unverified products.
What This Means for You
If you are currently using peptides or considering them, this episode is required listening. The space in March 2026 looks different from even six months ago. Buhler gives actionable information about what is available, how to vet providers, and what regulatory changes might be coming next.
If you are newer to all this, the episode also works as a solid introduction. Joe asks the basic questions that a newcomer would want answered, and Buhler explains without being condescending. You will come away with a clearer picture of why peptides matter, why access is controversial, and what the fight over them is really about.
With 364K views in less than two weeks, this is clearly hitting a nerve. People want to know what is going on with their access to these compounds, and Buhler is one of the few people willing to talk about it in detail on a massive platform.